BridgeBio Pharma, Inc. BBIO
65.57
(0.71)
(1.07%)
as of 25 Sep
- Market cap
- $13.1B
- P/E
- 0.0×
Follow BBIO
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 171.91 | 34.54 | 13.62 | 707.83 | 23.01 | 29.18 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | (48.34) | (87.17) | (17.98) | (11.34) | (52.76) | (26.14) | (259.66) |
P/B ratio |
— | — | 7.78 | 78.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | 7.78 | 78.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | 0.00 | 169.25 | 47.05 | 29.09 | 845.35 | 27.72 | 31.71 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | (12.77) | (20.67) | (6.59) | (5.38) | (14.90) | (11.81) | (35.70) |
EV/FCF |
— | — | (12.64) | (20.29) | (6.42) | (5.30) | (14.82) | (11.61) | (34.94) |
Quick Ratio |
10.22 | 13.39 | 9.09 | 6.35 | 6.34 | 4.34 | 3.15 | 4.44 | 2.52 |
Current Ratio |
10.78 | 13.67 | 9.42 | 6.72 | 6.58 | 4.52 | 3.32 | 4.67 | 2.77 |
Net Debt/EBITDA |
(1.19) | 2.08 | 1.68 | 0.27 | (1.53) | (2.38) | (2.15) | (1.80) | (2.47) |
Debt/Assets |
0.00% | 11.72% | 15.80% | 67.84% | 168.72% | 274.72% | 316.03% | 187.24% | 197.91% |
Debt/Equity |
0.00 | 0.14 | 0.21 | 4.49 | (1.97) | (1.38) | (1.29) | (1.18) | (0.89) |
Asset Turnover |
0.00 | 0.00 | 0.07 | 0.01 | 0.08 | 0.09 | 0.02 | 0.30 | 0.54 |
Operating CF/Net income |
1.32 | 1.05 | 0.97 | 0.89 | 0.89 | 0.87 | 0.82 | 0.97 | 0.62 |
Capex/Depreciation |
(1.78) | 0.00 | (3.07) | (5.16) | (8.26) | (0.93) | (0.08) | (0.66) | (0.84) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (24.07%) | (82.69%) | (61.24%) | (154.74%) | 147.89% | 45.60% | 49.74% | 38.26% | 41.03% | |
| (10.86%) | (56.24%) | (47.53%) | (67.21%) | (65.55%) | (58.83%) | (110.00%) | (73.11%) | (78.14%) | |
ROIC |
(52.71%) | 0.00% | (604.41%) | 0.00% | (7,261.64%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(34.73%) | (31.57%) | (50.71%) | (79.07%) | (71.77%) | (108.87%) | (186.13%) | (93.45%) | (140.72%) |
Average Days of Receivables |
— | — | 25.60 | 0.00 | 103.40 | 80.28 | 68.70 | 7.77 | 101.37 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 517.62% | 4,085.91% | 646.94% | 514.45% | 4,898.54% | 228.24% | 90.02% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 232.63% | 1,766.08% | 275.70% | 184.41% | 1,618.73% | 130.21% | 105.81% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.05 | 0.03 | 0.03 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 52.70% | 708.68% | 142.73% | 117.92% | 1,168.55% | 43.17% | 26.49% |
Graham Net Nets |
— | — | 0.11 | 0.01 | (0.41) | (1.25) | (0.21) | (0.32) | (0.15) |
Graham Number |
— | — | 0.00 | 0.00 | 22.99 | 24.91 | 27.04 | 22.41 | 30.36 |
Earnings Yield |
— | — | (7.65%) | (5.34%) | (23.44%) | (45.61%) | (9.74%) | (10.39%) | (4.94%) |
Free Cash Flow Yield |
— | — | (6.96%) | (4.85%) | (21.23%) | (40.27%) | (8.06%) | (10.37%) | (3.11%) |
Revenue per Share |
0.00 | 0.00 | 0.39 | 0.07 | 0.48 | 0.53 | 0.06 | 1.19 | 2.62 |
Operating CF per Share |
(1.32) | (2.21) | (2.41) | (3.39) | (3.45) | (2.84) | (3.24) | (2.80) | (2.33) |
Capex per Share |
(0.02) | (0.04) | (0.03) | (0.06) | (0.33) | (0.04) | (0.01) | (0.05) | (0.05) |
Free Cash Flow per Share |
(1.34) | (2.25) | (2.44) | (3.45) | (3.78) | (2.89) | (3.25) | (2.85) | (2.38) |
Cash per Share |
3.01 | 7.06 | 5.20 | 5.15 | 5.80 | 3.46 | 2.77 | 3.66 | 3.07 |
Shareholders Equity per Share |
0.00 | 6.11 | 4.51 | 0.90 | (6.01) | (8.43) | (8.25) | (7.83) | (10.84) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 6.11 | 4.51 | 0.90 | (6.01) | (8.43) | (8.25) | (7.83) | (10.84) |
Free Cash Flow |
(40.95) | (138.82) | (256.22) | (407.23) | (546.18) | (425.81) | (529.03) | (529.63) | (455.50) |
Working Capital |
88.00 | 412.65 | 508.24 | 547.18 | 753.79 | 427.43 | 333.75 | 566.29 | 509.78 |
Capital Expenditures |
(0.46) | (2.18) | (2.64) | (7.52) | (48.25) | (6.32) | (1.31) | (8.91) | (9.59) |
Net Current Asset Value |
97.00 | 357.52 | 410.68 | 45.49 | (990.94) | (1,317.52) | (1,411.80) | (1,656.40) | (2,214.29) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.91 | 0.69 | 0.08 | 0.14 | 0.04 | 0.02 |
Net Profit Margin |
0.00% | 0.00% | (642.47%) | (5,439.74%) | (806.90%) | (619.70%) | (6,913.92%) | (241.44%) | (144.39%) |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.15 | 0.07 | 0.19 | 0.46 | 1.30 | 1.93 | 2.12 |
Cash ROIC |
(17.16%) | (15.93%) | (23.15%) | (35.28%) | (31.45%) | (44.38%) | (64.60%) | (55.86%) | (124.00%) |
Accounts Receivable Turnover |
— | — | 3.55 | 0.00 | 6.17 | 4.22 | 0.99 | 68.56 | 6.97 |
Accounts Payable Turnover |
0.03 | 0.00 | 0.22 | 0.35 | 0.30 | 0.29 | 0.22 | 0.38 | 0.91 |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
2,807.69 | 0.00 | 1,292.39 | 1,057.29 | 1,392.95 | 1,228.50 | 1,589.97 | 905.25 | 630.82 |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 465.84 |
Average Receivables |
— | — | 11.42 | — | 11.30 | 18.41 | 9.42 | 3.24 | 72.08 |
Average Payables |
8.00 | 7.75 | 11.18 | 8.90 | 10.41 | 11.72 | 11.11 | 10.14 | 22.92 |
Average Assets |
281.50 | 232.47 | 548.31 | 667.63 | 858.19 | 817.91 | 584.71 | 732.86 | 927.68 |
Average Common Equity |
127.00 | 158.12 | 425.49 | 289.99 | (380.37) | (1,055.17) | (1,293.17) | (1,400.38) | (1,766.88) |
Columns are period end dates